NEA
Portfolio in South Korea · United States: 5 funded startups tracked by Uback, 4 of them in a ranking.
Portfolio on Uback
Sorted by Uback rank, then Radar by last round| Company | Uback | Sector | Round backed | Valuation (AI) |
|---|---|---|---|---|
| Xaira Therapeutics | #3 AI drug discovery | Healthtech › Biotech › AI drug discovery | Launch financing · USD 1B+ committed · Apr 2024 | Unicorn |
| Pathos AI | #5 AI drug discovery | Healthtech › Biotech › AI drug discovery | Series D · USD 365M · May 2025 | Unicorn |
| Factory | #5 Coding agents | Artificial intelligence › Agents › Coding agents | Growth round · USD 200M · Sep 2026 | Unicorn |
| Qualified Health | #8 Clinical software | Healthtech › Clinical software › Clinical software | Series B · USD 125M · Mar 2026 | Hundreds of M$ |
| Twelve Labs | Radar | AI › video understanding models | Series B · USD 100M · Jul 2026 | Not estimated |
Only startups that meet Uback’s eligibility rules are shown. Amounts are round sizes, not the fund’s share. Rounds as reported by public sources.
By sector
Deals tracked per year
Co-investors
Sequoia Capital ×2 · Naver Ventures · ARCH Venture Partners · Foresite Labs · F-Prime · Lux · Lightspeed · General Atlantic · Blackstone · Khosla Ventures · Insight Partners
Investors that joined the same rounds, as reported by public sources.
Sources. biospace.com, factory.ai, factory.com, fiercebiotech.com, finance.yahoo.com, finsmes.com, hlth.com, mobihealthnews.com, siliconangle.com, thenextweb.com, as cited on each company’s profile.
Last updated: Oct 2026Report a missing dealReport an error
Uback is a content publisher. It provides no investment advice, receives no mandate and takes part in no transaction.